Andelyn Biosciences and Armatus Bio Collaborate to Manufacture Gene Therapy for Charcot-Marie-Tooth Type 1A (CMT1A)
Shots:
- Andelyn Biosciences and Armatus Bio have partnered to expedite the manufacturing of gene therapy for treating Charcot-Marie-Tooth Type 1A (CMT1A)
- Under the terms of the agreement, Armatus will utilize Andelyn's expertise in adeno-associated virus (AAV) production and its proprietary suspension platform for the development activities, plasmid manufacturing, viral vector toxicology and GMP clinical manufacturing
- The collaboration aims to increase the efficiency of the program and speed up the clinical studies of this precision method
Ref: Andelyn | Image: Andelyn
Related News:- SpliceBio Signs an Exclusive Collaboration and License Agreement with Spark Therapeutics to Develop Gene Therapy
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Shivani is a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
